Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Laustsen, Julie K ^a,b   Rasmussen, Tue K ^a,b   Stengaard Pedersen, Kristian ^a,b   Hørslev Petersen, Kim ^c   Hetland, Merete L ^d,e   Østergaard, Mikkel ^d,e   Junker, Peter ^f   Hvid, Malene ^a   Deleuran, Bent ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; BETAMETHASONE; C REACTIVE PROTEIN; CD134 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; METHOTREXATE; OX40 LIGAND; PLACEBO; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; MONOCLONAL ANTIBODY; TNFRSF4 PROTEIN, HUMAN; TNFSF4 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIMPLIFIED DISEASE ACTIVITY INDEX; SYNOVIAL FLUID; T LYMPHOCYTE; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; SOLUBILITY; TIME FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; OX40 LIGAND; PEPTIDES, CYCLIC; RECEPTORS, OX40; SOLUBILITY; SYNOVIAL FLUID; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84990876677     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0474-4     Document Type: Article

References (26)

1. McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
2. Wang Q, Chen Y, Xie F, Ge Y, Chen L, Wu H, Qu Q, Wang X, Zhang X: Development of a sandwich ELISA for evaluating soluble OX40L (CD252) in human sera of different ages or with Graves' disease. Cytokine 2006, 36:23-28.
3. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455.
4. Qin W, Hongya W, Yongjing C, Fang X, Yue M, Xuekun Z, Xiaozhong L, Xueguang Z: Increased OX40 and soluble OX40 ligands in children with Henoch-Schonlein purpura: association with renal involvement. Pediatr Allergy Immunol 2011, 22:54-59.
5. Soroosh P, Ine S, Sugamura K, Ishii N: OX40-OX40 Ligand Interaction through T Cell-T cell contact contributes to CD4 T Cell longevity. J Immunol 2006, 176:5975-5987.
6. Sibilano R, Gri G, Frossi B, Tripodo C, Suzuki R, Rivera J, MacDonald AS, Pucillo CE: Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcεRI-dependent mast cell degranulation. J Leukoc Biol 2011, 90:831-838.
7. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M: The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000, 165:3043-3050.
8. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA: Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996, 2:183-189.
9. Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, Lane PJL: OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011, 244:134-148.
10. Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YMF, Miller LA, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F: In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest 2007, 117:3868-3878.
11. Weinberg ADA, Wegmann KWK, Funatake CC, Whitham RHR: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999, 162:1818-1826.
12. Burrell BE, Lu G, Li XC, Bishop DK: OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol 2009, 182:379-390.
13. Wang Q, Chen Y, Ge Y, Sun J, Shi Q, Ju S, Dai J, Yu G, Zhang X: Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 2004, 64:566-574.
14. Stüber EE, Strober WW: The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996, 183:979-989.
15. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K: Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000, 30:2815-2823.
16. Gwyer Findlay E, Danks L, Madden J, Cavanagh MM, McNamee K, McCann F, Snelgrove RJ, Shaw S, Feldmann M, Taylor PC, Horwood NJ, Hussell T: OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci USA 2014, 111:2289-2294.
17. Van der Maas A, Lie E, Christensen R, Choy E, De Man YA, Van Riel P, Woodworth T, Broeder den AA: Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013, 72:1800-1805.
18. Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M: A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients. Springerplus 2013, 2:263.
19. Joyce DAD, Steer JHJ: Tumor necrosis factor alpha and interleukin-1 alpha stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes. J Interferon Cytokine Res 1995, 15:947-954.
20. Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Ostergaard M, Stengaard-Pedersen K, OPERA study-group: Adalimumab added to treatto-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study: an investigator-initiated, randomised, doubleblind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2014, 73:654-661.
21. França ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-Schainberg C, Laurindo IMM, Precioso AR, Ishida MA, Sartori AMC, Silva CA, Bonfa E: TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 2012, 51:2091-2098.
22. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, Sugihara T, Nonomura Y, Hirose W, Nagasaka K, Sakurai T, Miyasaka N: Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007, 17:531-533.
23. Van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HMJ, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF: Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011, 70:1389-1394.
24. Breedveld F: The value of early intervention in RA-a window of opportunity. Clin Rheumatol 2011, 30:S33-S39.
25. Kroeger DR, Rudulier CD, Bretscher PA: Antigen presenting B cells facilitate CD4 T cell cooperation resulting in enhanced generation of effector and memory CD4 T cells. PLoS One 2013, 8:e77346.
26. Willemze A, Böhringer S, Knevel R, Levarht EWN, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, Van der Helm-van Mil AHM, Huizinga TWJ, Toes REM, Trouw LA: The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012, 71:268-274.